This Article Full Text Full Text (PDF) All Versions of this Article: 39/11/2993    most recent STROKEAHA.108.520668v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cucchiara, B. Search for Related Content PubMed PubMed Citation Articles by Cucchiara, B. Pubmed/NCBI databases Medline Plus Health Information Blood Thinners Related Collections Coumarins Acute Cerebral Hemorrhage Intracerebral Hemorrhage Anticoagulants

(Stroke. 2008;39:2993.)
© 2008 American Heart Association, Inc.

Original Contributions

Hematoma Growth in Oral Anticoagulant Related Intracerebral Hemorrhage

Brett Cucchiara, MD; Steven Messe, MD; Lauren Sansing, MD; Scott Kasner, MD; Patrick Lyden, MD for the CHANT Investigators

From the Department of Neurology (B.C., S.M., L.S., S.K.), University of Pennsylvania Medical Center, Philadelphia; and the Department of Neurology (P.S.L.), University of California, San Diego.

Correspondence to Brett Cucchiara, MD, Department of Neurology, University of Pennsylvania Medical Center, 3400 Spruce Street, Philadelphia, PA 19104. E-mail cucchiar{at}mail.med.upenn.edu

Background and Purpose— Limited data suggest that intracerebral hemorrhage related to oral anticoagulant therapy (OAT ICH) is associated with more hemorrhage expansion and a worse prognosis than spontaneous ICH (SICH).

Methods— We examined patients enrolled in the placebo arm of the CHANT study, a prospective randomized trial of a putative neuroprotectant in patients with ICH. All patients had neuroimaging within 6 hours of symptom onset and at 72 hours. Initial ICH volume and hemorrhage expansion were determined by a central reader. Multivariable logistic regression was used to determine factors associated with ICH expansion and mortality at 90 days.

Results— Of 303 patients included, 21 (6.9%) had OAT ICH. Baseline median ICH volume was greater in patients with OAT ICH compared to SICH (30.6 versus 14.4 mL, P=0.03). Hemorrhage expansion (defined as >33% increase in ICH volume) occurred in 56% of patients with OAT ICH compared to 26% of SICH (P=0.006). Mortality was substantially higher in OAT ICH (62% versus 17%, P<0.001). In multivariable analysis, time to neuroimaging and oral anticoagulant use were independently associated with hemorrhage expansion, and age, gender, and oral anticoagulant use were independently associated with mortality.

Conclusions— These findings confirm that OAT ICH is associated with more hemorrhage expansion and greater mortality than SICH.

Key Words: warfarin • intracerebral hemorrhage • anticoagulation

This article has been cited by other articles:

				N. Liu, S. Aldea, D. Francois, M. Cherqui-Michel, M. Giansily-Blaizot, and M. Fischler Recombinant activated factor VII for a patient with factor VII deficiency undergoing urgent intracerebral haematoma evacuation with underlying cavernous angioma Br. J. Anaesth., December 1, 2009; 103(6): 858 - 860. [Abstract] [Full Text] [PDF]

				E. Zia, G. Engstrom, P. J. Svensson, B. Norrving, and H. Pessah-Rasmussen Three-Year Survival and Stroke Recurrence Rates in Patients With Primary Intracerebral Hemorrhage Stroke, November 1, 2009; 40(11): 3567 - 3573. [Abstract] [Full Text] [PDF]

				M. L. Flaherty, O. Adeoye, P. Sekar, M. Haverbusch, C. J. Moomaw, H. Tao, J. P. Broderick, and D. Woo The Challenge of Designing a Treatment Trial for Warfarin-Associated Intracerebral Hemorrhage Stroke, May 1, 2009; 40(5): 1738 - 1742. [Abstract] [Full Text] [PDF]

				J. P. Broderick Evidence against rapid reversal of antiplatelet medications in acute intracerebral hemorrhage Neurology, April 21, 2009; 72(16): 1376 - 1377. [Full Text] [PDF]